Piramal Pharma Gets FDA Form-483 for Lexington Unit - scanx.trade
Piramal Pharma's Lexington facility received an FDA Form-483, indicating potential cGMP violations. This may affect supply chain reliability for clients relying on this contract manufacturer.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) that use or rely on Piramal's Lexington facility. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Within 30 days to mitigate potential supply disruptions.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a Form-483 after inspection, citing deviations from current good manufacturing practice (cGMP). This could lead to warning letters, consent decrees, or shutdown if not resolved.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) that use or rely on Piramal's Lexington facility.
What you must do
Assess exposure to Piramal Lexington products; review supply agreements for contingency clauses; identify alternative suppliers for critical materials.
Deadline
Within 30 days to mitigate potential supply disruptions.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)